- Home
- Publications
- Publication Search
- Publication Details
Title
Breakthrough in targeted therapy for non-small cell lung cancer
Authors
Keywords
Non-small cell lung cancer, Targeted therapy, Chemotherapy, EGFR, ALK
Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 133, Issue -, Pages 111079
Publisher
Elsevier BV
Online
2020-12-04
DOI
10.1016/j.biopha.2020.111079
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genetic variants in RET, ARHGEF3 and CTNNAL1, and relevant interaction networks, contribute to the risk of Hirschsprung disease
- (2020) Yang Wang et al. Aging-US
- TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
- (2020) G.R. Oxnard et al. ANNALS OF ONCOLOGY
- Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
- (2020) F. Guisier et al. BMC CANCER
- Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma
- (2020) Anastasios Dimou et al. BMC CANCER
- piRNAs: biogenesis and their potential roles in cancer
- (2020) Binghong Guo et al. CANCER AND METASTASIS REVIEWS
- The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
- (2020) Giuseppe Nicolò Fanelli et al. Cancer Cell International
- Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
- (2020) Adam J Schoenfeld et al. CLINICAL CANCER RESEARCH
- MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
- (2020) Ibiayi Dagogo-Jack et al. CLINICAL CANCER RESEARCH
- Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC
- (2020) Gonzalo Recondo et al. CLINICAL CANCER RESEARCH
- GWAS in cancer: progress and challenges
- (2020) Baiqiang Liang et al. MOLECULAR GENETICS AND GENOMICS
- Targeted drugs ramp up cancer mutability
- (2020) Marco Gerlinger SCIENCE
- Cancer immunotherapy: Pros, cons and beyond
- (2020) Shuzhen Tan et al. BIOMEDICINE & PHARMACOTHERAPY
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Disease and Androgen Axis–Targeted Drugs for Prostate Cancer
- (2020) Celestia S. Higano NEW ENGLAND JOURNAL OF MEDICINE
- mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
- (2020) Zhilin Zou et al. Cell and Bioscience
- Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
- (2020) Noriko Hirai et al. Frontiers in Oncology
- Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses
- (2020) Binghao Zhao et al. Aging-US
- The emerging roles of artificial intelligence in cancer drug development and precision therapy
- (2020) Guosheng Liang et al. BIOMEDICINE & PHARMACOTHERAPY
- Systems analysis of protein signatures predicting cetuximab responses in KRAS , NRAS , BRAF and PIK3CA wild‐type patient‐derived xenograft models of metastatic colorectal cancer
- (2020) Andreas U. Lindner et al. INTERNATIONAL JOURNAL OF CANCER
- Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
- (2020) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy
- (2020) Gemma Bruera et al. Frontiers in Oncology
- Targeting the GRP78 Pathway for Cancer Therapy
- (2020) Guanhua Lu et al. Frontiers in Medicine
- Big data-driven precision medicine: Starting the custom-made era of iatrology
- (2020) Chang Song et al. BIOMEDICINE & PHARMACOTHERAPY
- How to overcome the side effects of tumor immunotherapy
- (2020) Shang Li et al. BIOMEDICINE & PHARMACOTHERAPY
- Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients
- (2020) Luciene Schluckebier et al. BMC CANCER
- Clinical and molecular spectra of BRAF-associated RASopathy
- (2020) Yena Lee et al. JOURNAL OF HUMAN GENETICS
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF Alteration in Central and Peripheral Nervous System Tumors
- (2020) Komal Srinivasa et al. Frontiers in Oncology
- Targeting the untargetable KRAS in cancer therapy
- (2019) Pingyu Liu et al. Acta Pharmaceutica Sinica B
- Efficacy and Safety of Ceritinib (450 mg/day or 600 mg/day) With Food vs 750 mg/day Fasted in Patients With ALK-Positive NSCLC: Primary Efficacy Results From ASCEND-8 Study
- (2019) Byoung Chul Cho et al. Journal of Thoracic Oncology
- Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study
- (2019) D. Ross Camidge et al. Journal of Thoracic Oncology
- 109OEntrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
- (2019) F Barlesi et al. ANNALS OF ONCOLOGY
- Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
- (2019) A T Shaw et al. ANNALS OF ONCOLOGY
- A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.
- (2019) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial
- (2019) Dung-Tsa Chen et al. Translational Cancer Research
- Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs
- (2019) Clemens-Martin Wendtner Lancet Haematology
- 444PDSafety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
- (2019) A Drilon et al. ANNALS OF ONCOLOGY
- 1478OResults of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain
- (2019) L Q Chow et al. ANNALS OF ONCOLOGY
- 1545PBrigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): The use via expanded access to brigatinib (UVEA-Brig) study
- (2019) S Novello et al. ANNALS OF ONCOLOGY
- RET-Rearranged Lung Adenocarcinoma with Paraneoplastic Meige Syndrome
- (2019) Baptiste Abbar et al. Journal of Thoracic Oncology
- Transcriptome analysis reveals an important candidate gene involved in both nodal metastasis and prognosis in lung adenocarcinoma
- (2019) Xiao Zhu et al. Cell and Bioscience
- circ5912 suppresses cancer progression via inducing MET in bladder cancer
- (2019) Yinjie Su et al. Aging-US
- In Vitro Assessment of Antitumor Potential and Combination Effect of Classical and Molecular-targeted Anticancer Drugs
- (2019) YOSUKE IIJIMA et al. ANTICANCER RESEARCH
- Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
- (2019) Jang Ho Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study
- (2019) Simon Baldacci et al. Journal of Thoracic Oncology
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
- (2019) Alexander Drilon et al. LANCET ONCOLOGY
- Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer
- (2019) Maurice Pérol et al. LUNG CANCER
- Circular RNAs: The star molecules in cancer
- (2019) Jianhong Liu et al. MOLECULAR ASPECTS OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers HarboringBRAF V600EMutations
- (2018) Lauretta Odogwu et al. ONCOLOGIST
- Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study
- (2018) Yutaka Fujiwara et al. Oncotarget
- Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
- (2018) Makoto Nishio et al. Cancer Research and Treatment
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis
- (2018) Eli L. Diamond et al. JAMA Oncology
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- (2018) Benjamin J Solomon et al. LANCET ONCOLOGY
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
- (2017) Sun Min Lim et al. JOURNAL OF CLINICAL ONCOLOGY
- MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers
- (2017) Oliver Gautschi et al. Journal of Thoracic Oncology
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- (2017) Jean-Charles Soria et al. LANCET
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
- (2017) Kiyotaka Yoh et al. Lancet Respiratory Medicine
- PS-1FIRST-LINE CRIZOTINIB VS PEMETREXED + CISPLATIN/CARBOPLATIN IN ASIAN PATIENTS WITH ADVANCED ALK+ NSCLC IN PROFILE 1014
- (2017) Kazuhiko Nakagawa et al. ANNALS OF ONCOLOGY
- Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients WithALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
- (2016) Lucio Crinò et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- (2016) Dong-Wan Kim et al. LANCET ONCOLOGY
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- (2015) Helen Y. Zou et al. CANCER CELL
- Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer--data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)
- (2015) E. Miyauchi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells
- (2015) Hui-Mei Wu et al. Scientific Reports
- Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
- (2013) Yuankai Shi et al. LANCET ONCOLOGY
- Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response
- (2012) Jaya Sangodkar et al. JOURNAL OF CLINICAL INVESTIGATION
- First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
- (2012) Ji-Youn Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
- (2012) Zhao Chen et al. NATURE
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
- (2011) Y. S. Ju et al. GENOME RESEARCH
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
- (2011) Ting-Lei Gu et al. PLoS One
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
- (2010) Ryoichi Onozato et al. Journal of Thoracic Oncology
- Single nucleotide polymorphism of rs430397 in the fifth intron ofGRP78gene and clinical relevance of primary hepatocellular carcinoma in Han Chinese: Risk and prognosis
- (2009) Xiao Zhu et al. INTERNATIONAL JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search